Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.61 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.59 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.59 |
| ▸ | CCR5 | P51681 | 11/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22767607 | 0.89 | CHRNA7 (0.73) | CHRNA7CHRNB2CHRNA4CCR5F10 | |
| SCHEMBL15429134 | 0.87 | CHRNB2 (0.74) | CHRNA7CHRNB2CHRNA4CCR5PABPC1 | |
| SCHEMBL6773387 | 0.82 | CHRNA7 (0.43) | CHRNA7CHRNB2CHRNA4CCR5PABPC1 | |
| SCHEMBL14951084 | 0.81 | CHRNB2 (0.67) | CHRNA7CHRNB2CHRNA4CCR5 | |
| SCHEMBL1983107 | 0.79 | CHRNA7 (0.61) | CHRNA7CHRNB2CHRNA4CCR5 | |
| SCHEMBL12682791 | 0.79 | CHRNB2 (0.65) | CHRNA7CHRNB2CHRNA4CCR5APOBEC3A | |
| SCHEMBL17853859 | 0.79 | CHRNA7 (0.56) | CHRNA7CHRNB2CHRNA4CCR5PABPC1 | |
| SCHEMBL3681307 | 0.78 | CHRNA7 (0.60) | CHRNA7CHRNB2CHRNA4CCR5PABPC1 | |
| SCHEMBL20017818 | 0.78 | CHRNB2 (0.62) | CHRNA7CHRNB2CHRNA4CCR5PABPC1 | |
| SCHEMBL6771829 | 0.77 | CHRNA7 (0.61) | CHRNA7CHRNB2CHRNA4CCR5PABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825187-B2 | CARBAPENEM DERIVATIVES SUBSTITUTED AT THE 2-POSITION WITH A SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP; USE AGAINST ANTIBIOTIC RESISTANT STAPHYLOCOCCUS AUREUS AND PSEUDOMONAS AERUGINOSA, ENTEROCOCCI AND INFLUENZA VIRUS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-11-30 | — | — | US | disclosed |
| US-20030022881-A1 | Novel carbapenem derivatives of quarternary salt type | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
| EP-1251134-A1 | NOVEL CARBAPENEM DERIVATIVES OF QUATERNARY SALT TYPE | MEIJI SEIKA KAISHA LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022881-A1 | Novel carbapenem derivatives of quarternary salt type | DHPS, HDHD5, RRP15 | CHRNA7 4408/4885CHRNB2 4501/4885CHRNA4 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.